@Mphasis financial result Q2fy21
Established as product challenger - ISG Next Gen Hybrid cloud data services 2020
AWS launch partner for airline,focus on healthcare,trade finance
Major contender as per Everest fr Cloud native Dev services 2020
New partnerships - Snowflake
#Nifty
Highest overall QoQ CC organic growth in over a decade
Highest quarterly revenue of $327.4mn ,crosses pre covid peak of Q4'20
Direct business : achieves $1bn annualized run rate

BCM : Consistent track record of double digit YOY growth
QoQ growth 17.4%,best in class
#stocks
Insurance: QoQ overall growth 2.5% ,strong pipeline visibility
Broad based & strong growth across verticals in direct business
Europe grew 8.2% YoY in Q2'21 in CC,direct business Europe grew 23% YoY in CC
#5G
#innovation #AI #cybersecurity #IoT #sensex
@Mphasis
Q2'21 direct TCV wins of $360mn
Highest ever quarterly TCV win for a quarter, includes one large deal of > $200mn
US$ 1BN+ TCV (TTM) ,up 74% Y/Y vs prior period, 75% increase in deal pipeline end of Q2'21
3rd consecutive quarter of $200mn TCV wins
73% of Q2'21 deal wins came from New-gen areas,95% YoY growth in New-gen TCV wins
Our new gen wins are witnessing increased deal sizes

Consistent improvement in client pyramid driven by expansion of wallet share in large clients & consistent new client wins
#mphasis
Healthy conversion of clients at each stage to the next ,50% conversion rate
Past 12 months added :
2 clients in > $75 mn
1 client in > $20mn
3 clients in > $ 10mn
4 clients in > $1mn

Strong QoQ & YoY growth in direct business
New clients revenue grew 29.4% YoY in Q2'21
Europe region delivers strong growth, growing at a healthy 3 year CAGR of 17%

Operating profit growth CAGR 18%
EPS growth CAGR 18.9%

Robust growth revenue overtaking prepandemic level
Highest sequential organic growth in over a decade
#nifty #sensex #StockMarket
Sequential double digit growth in Direct,growth supported by rising TCV trend,highest ever TCV at $360mn
TCV(TTM) crosses $1bn,up 74% over prior period
Track record winning deals improving,consistent deal wins,increasing deal sizes,$50 - $100 -$200 mn
Record deal pipeline ( up over 75% YoY) characterized by multiple large deal pursuits
Healthy 50% conversion in converting client from one bucket to the next
Building visibility in DXC beyond Sep'21,strong business & operational realignment in DXC relationships
#mphasis

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with TheMarket🐝

TheMarket🐝 Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @BullsforBears

22 Oct
#valiantorganic
Speciality chemicals player
Promoters -Hemchand gala(original promoter),now Gogris of Aarti industries
Manufactures & markets Chlorophenols
Facility -fully integrated
Raw material - for Chlorophenol( Chlorine gas & phenol)
Chlorine easily available,phenol import
Industrial use for products in agrochemicals, dyes,pigments,pharma,veterinary,cosmetics

First SME IPO where MF took stake ,Reliance MF
Initially listed on SME platform,got listed on @bse in Sep 20 & @NSEIndia on 5th Oct20

Paying dividends since 2017
In 2017 company merged Abhilasha Tex chemicals into itself
Merger with Amarjyot chemicals expanded product portfolio to dues,pigments,pharma,agrochemicals

Drawbacks - Chinese players,top 10 clients contribute 75% business,sourcing of raw Material 80% from top 10 suppliers
Read 11 tweets
7 Oct
Nikunj dalmia in conversation with Saurabh Mukherjee on @ETNOWlive

@HDFCLIFE - brought big data to their life insurance business
More questionnaire compared to other insurance players
More rigorous health checkups
Better underwriting & embedded value due to big data use
Another player using big data @BajajFinCorp - superior ROE compared to other NBFCs

Move to complete digitization helping IT firms
@TCS reorients itself according to need of its fortune 500 clients ,moved from infrastructure software to application development to big data,cloud
@TCS ability to retrain lakhs of employees as per need is a big advantage

Next 3 months economic outlook to remain upbeat as Indis opens up
Small town real estate mkt is picking pace
Strong commentary from @HomeLoansByHDFC guided to strong recovery
Post lockdown pickup
Read 8 tweets
1 Oct
#RakeshJhunjhunwala on @ETNOWlive

1991 moment for Agriculture
Better pricing power for farmers
Structural reforms in transport & logistics sector to ramp up
India to be the pharma capital of the world
Underownwrship of equities in India
#Nifty #sensex #StockMarket
Percentage of corporate profits to GDP low in India
Api & generic companies to have both earnings & PE expansion
India focused pharma companies to have earnings but not PE expansion
Current pharma rally may last longer than previous rally
#Nifty #traders #stocks #markets
Electric vehicle adaptation in India will be faster than anticipated
Climate change to drive consumer behavior
Recovery from #COVID19 faster than expected
Oppurtunity in Infra,Hotels sector
Value stocks @ITCCorpCom @TheOfficialSBI to gain in 2nd phase of bull mkt
@ETNOWlive
Read 6 tweets
30 Aug
Niraparib,orally active small molecule PARP inhibitor developed by Tesaro to Rx ovarian cancer, granted fast track designtn by USFDA in 2016
Apr'20 USFDA approved Zejula (niraparib) as monotherapy maintenance Rx for ovarian,fallopian tube,peritoneal cancer
@GSK
#dishmanpharma
Dishman Carbogen makes the API for the drug, has been supplying APIs to GSK from 2017
The approval will help Niraparib grow multifold,big positive for Dishman’s CRAMS business.
Niraparib API revenues for Dishman could grow twofold next 2 yrs
#dishmancarbogenamcis #DCAL #niraparib
Zejula is currently approved as a maintenance therapy for adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer and whose tumors have completely or partially responded to platinum-based chemotherapy treatments
Zejula sales $295 million 2019
#dcal
Read 4 tweets
26 Aug
@SunPharma_Live
(In Million) fy11/fy20
Revenue - 60827/334735
R&D - 3313/19736
Net Profit - 18161/69644
EPS - 7.5/15.7

New speciality launche
1) Cequa -Oct'19 (cyclosporine ophthalmic solution 0.09%)in Keratoconjunctivitis sicca(dry eye) for increasing tear productn
#pharma
2) Absorica LD - Feb'20(isotretinoin) capsules in US for severe recalcitrant acne in patients 12yrs&older

3) Ezallor sprinkle - July'19(rosuvastatin)capsules for 3 types of elevated lipid disorders for patients with difficulty in swallowing

#pharma #StockMarket #Nifty #stocks
4)Drizalma Sprinkle - Oct'19(duloxetine delayed release capsules) in US for oral use, serotonin & norepinephrine reuptake inhibitor for patients with neuropsychiatric & pain disorders in patients who have difficulty swallowing

@SunPharma_Live annual report 2019/20
#API #sensex
Read 11 tweets
22 Aug
Cipla Mkt share in Fluticasone propionate salmeterol pMDI is 20% in EU
#2 in sale of inhalers globally
Respiratory 22% share in total revenues
Foracort #10 among 4 @Cipla_Global brands that featured in top 50 brands in India
46% in MDIs & 65% in FPSM pMDI Mkt share in S Africa
@Cipla_Global role in #COVID__19
Scaling up supply of Lopinavir+Ritonavir,HCQ,Azithromycin
Partnered with @Roche for #tocilizumab
Partnered with @GileadSciences for #remdesivir to manufacture & market in 127 countries
With CSIR-IICT for #favipiravir
Cipla in India 2020
$1bn orgnizatn,40% of revenue
Leadership in respiratory,urology,anti-virals
Launched foracort syncobreathe
Acquired brand & trademark for Vysov&Vysov M
Deal for Omalizumab(Allergic Asthma)with Reliance lifesciences
Stempeucel used in DM
Acq 4nutraceuticals
Read 16 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!